Prevention

What the evidence supports doing now.

Taiwan Cohort Splits GLP-1's Dementia Benefit: Real, but Not for Alzheimer's

A propensity-matched study of more than 21,000 Taiwanese adults with type 2 diabetes found GLP-1 receptor agonists nearly halved the risk of an overall dementia diagnosis compared with long-acting insulin, but the benefit vanished when Alzheimer's disease and vascular dementia were analyzed on their own.

Forty-nine out of 61: where dementia prevention keeps pointing

A new Lancet Public Health Viewpoint from Curtin University sorts every published modifiable dementia factor by where it actually operates. Four in five sit inside the individual. The authors say that says more about the research than about the risk.

Four-Year Trial Ties Structured Exercise to Better Cognitive Scores in Healthy Seniors, Weaker Signal in Those With Memory Complaints

A single-blind randomized trial that followed 882 older adults in Italy for 48 months found higher Mini-Mental State Examination scores among cognitively healthy participants assigned to supervised exercise, but a smaller and statistically borderline effect in those with subjective memory complaints, and too few participants with mild cognitive impairment to draw conclusions.

The eye chart that turned up in the dementia risk ledger

A JAMA Neurology model put 1.8 percent of US dementia cases, more than 100,000 people, in the column marked vision impairment. A second, sharper measurement pushed the figure far higher. Neither study proves cause, and both changed the conversation about eye care.

The guideline that arrived just before the drugs did

An American surgical society rewrote its thiamine advice in April 2025, raising the dose recommended before weight-loss surgery and before weight-loss medication. A year later, a review of Wernicke's cases in people taking semaglutide showed why that sentence mattered.

The prevention window opens in the late thirties

A Barcelona cohort dates the moment blood and spinal fluid tau in Down syndrome part company with everyone else's: about 37 years for plasma p-tau217. It is the most decision-relevant number in Down syndrome prevention, and it lands years before most trials open their doors.

The childhood reading struggle that shows up in a dementia gene score

An Amsterdam-led preprint finds polygenic scores for developmental dyslexia running high in semantic variant primary progressive aphasia, and only in the men. It is the first genetic hint behind the one risk factor PPA leaflets have always named, and it changes nothing anyone can do today.

In PPA, brain stimulation moved two things: naming and spelling

A 2025 meta-analysis pooled ten randomised trials of transcranial direct current stimulation in primary progressive aphasia. General naming and spelling improved. Everything else measured did not. Families asking about home devices deserve the pooled figure, not the best anecdote.

Six Months of Magnetic Pulses, and a Gap of 0.02 on a PET Scan

A Madrid trial gave 63 people with primary progressive aphasia half a year of theta-burst stimulation and word therapy. It is the longest sham-controlled test the syndrome has had. Its main result was a difference in brain metabolism so small the researchers themselves will not say what it means for a life.

The Vitamin That Never Made It Into the Glass

For nearly fifty years, doctors have argued that putting thiamine in beer would prevent Korsakoff syndrome in the people least likely to ever ask for a prescription. Australia came closest, then put it in bread instead. A new peer-reviewed history asks what that swap actually bought.